Key result
An international workshop summarized the definition, ethical aspects, and clinical trial results regarding the controversial use of growth hormone for children with idiopathic short stature.
Why the study?
Should children with idiopathic short stature be treated with growth hormone?
Should children with idiopathic short stature be treated with growth hormone?
This workshop summary outlines the controversies and considerations surrounding growth hormone treatment for children with idiopathic short stature.
Ethical concerns and limited long-term data caution against routine growth hormone use in idiopathic short stature; leaves open need for standardized trials.
The use of growth hormone (GH) to treat short children who are clearly GH-deficient is now well accepted. However, GH treatment of short children who have no currently recognizable abnormalities in their GH-insulin-like growth factor I axis remains controversial. Whether such children with so-called idiopathic short stature (ISS) should be treated with GH was the subject of an international workshop held in St.-Paul-de-Vence, France, in April 1999. This article summarizes the issues discussed at the workshop, including the definition of ISS, ethical and health-economic aspects of treatment, results from clinical trials and surveillance studies, and the use of prediction models in aiding treatment decisions.
No takes yet. Share an insight, caveat, or question.
Kelnar et al. (1999) conducted a review in Idiopathic short stature. Growth hormone was evaluated. An international workshop summarized the definition, ethical aspects, and clinical trial results regarding the controversial use of growth hormone for children with idiopathic short stature.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: